This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Board meeting on Oct 30 to consider Q2 FY26 results
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.3 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies has informed BSE that a board meeting is scheduled on Friday, October 30, 2026, to consider and approve unaudited standalone and consolidated financial results for the second quarter and half year ended September 30, 2026. The trading window for dealing in the company's securities remains closed till November 1, 2026.
Routine procedural filing; investors should await the actual Q2 results on October 30 for any meaningful performance update.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹441.2 Cr | ₹361.1 Cr | +22.2% |
| Operating profit | ₹78.14 Cr | ₹67.34 Cr | +16.0% |
| Profit after tax | ₹60.31 Cr | ₹52.32 Cr | +15.3% |
| EBITDA margin | 21.8% | 21.7% | +0.0 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.